Research ArticleClinical Investigation
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
Michal Eifer, Duncan E.K. Sutherland, Isaac Goncalves, James P. Buteau, Lewis Au, Arun A. Azad, Louise Emmett, Grace Kong, Louise Kostos, Aravind S. Ravi Kumar, Edmond M. Kwan, Elizabeth Medhurst, Shahneen Sandhu, Ben Tran, Alexander W. Wyatt and Michael S. Hofman
Journal of Nuclear Medicine April 2025, 66 (4) 579-584; DOI: https://doi.org/10.2967/jnumed.124.268640
Michal Eifer
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
2Department of Diagnostic Imaging, Chaim Sheba Medical Center, Ramat Gan, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
Duncan E.K. Sutherland
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Isaac Goncalves
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
James P. Buteau
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
Lewis Au
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Arun A. Azad
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Louise Emmett
5Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia, and Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia; and
Grace Kong
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
Louise Kostos
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Aravind S. Ravi Kumar
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
Edmond M. Kwan
6Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
Elizabeth Medhurst
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
Shahneen Sandhu
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Ben Tran
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Alexander W. Wyatt
6Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
Michael S. Hofman
1Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
3Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 4
April 1, 2025
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
Michal Eifer, Duncan E.K. Sutherland, Isaac Goncalves, James P. Buteau, Lewis Au, Arun A. Azad, Louise Emmett, Grace Kong, Louise Kostos, Aravind S. Ravi Kumar, Edmond M. Kwan, Elizabeth Medhurst, Shahneen Sandhu, Ben Tran, Alexander W. Wyatt, Michael S. Hofman
Journal of Nuclear Medicine Apr 2025, 66 (4) 579-584; DOI: 10.2967/jnumed.124.268640
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
Michal Eifer, Duncan E.K. Sutherland, Isaac Goncalves, James P. Buteau, Lewis Au, Arun A. Azad, Louise Emmett, Grace Kong, Louise Kostos, Aravind S. Ravi Kumar, Edmond M. Kwan, Elizabeth Medhurst, Shahneen Sandhu, Ben Tran, Alexander W. Wyatt, Michael S. Hofman
Journal of Nuclear Medicine Apr 2025, 66 (4) 579-584; DOI: 10.2967/jnumed.124.268640
Jump to section
Related Articles
Cited By...
- No citing articles found.